NCT00482703 - A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Myeloid Leukemia, Chronic

Interventions

DRUG

Dasatinib

tablets, Oral, 100 mg, once daily

DRUG

dasatinib

tablets, Oral, 50 mg, twice daily

Trial Locations (9)

Local Institution, Nagoya

Local Institution, Nishinomiya-Shi

Local Institution, Kagoshima

Local Institution, Isehara-Shi

Local Institution, Kyoto

Local Institution, Hamamatsu

Local Institution, Bunkyo-Ku

Local Institution, Chuo-Ku

Local Institution, Shibuya-Ku